Fortress Biotech (FBIO) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
OS Therapies (OSTX) has outperformed Fortress Biotech (FBIO) over the past year, losing 28.6% versus a loss of 30.7%. Fortress Biotech is the larger company by market cap ($62.4 million vs $61.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | OSTX |
|---|---|---|
| Share price | $1.87 | $1.32 |
| Market cap | $62.37M | $61.78M |
| 1-day change | -2.09% | -6.38% |
| YTD return | -48.91% | -5.71% |
| 1-year return | -30.74% | -28.65% |
| 5-year return | -95.84% | — |
| P/E ratio (TTM) | 0.68 | — |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $2.76 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | — |
| Revenue growth (YoY) | +9.69% | — |
| Net income (latest FY) | $6.82M | $-28.75M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | — |
| Net margin | 10.77% | — |
| 52-week high | $4.53 | $2.25 |
| 52-week low | $1.84 | $1.15 |
| Distance from 52-week high | -58.72% | -41.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +167.38% | +543.94% |
| Average volume | 448.52K | 578.15K |
| Shares outstanding | 33.35M | 46.81M |
| Employees | 78 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
FBIO vs OSTX FAQ
Which is bigger, Fortress Biotech or OS Therapies?
Fortress Biotech (FBIO) is larger, with a market capitalization of $62.37M compared with $61.78M for OS Therapies (OSTX).
Which stock has performed better over the past year, FBIO or OSTX?
OSTX returned -28.65% over the past 12 months, compared with -30.74% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.